182 related articles for article (PubMed ID: 24108701)
1. Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity.
Chen S; Li Y; Depontieu FR; McMiller TL; English AM; Shabanowitz J; Kos F; Sidney J; Sette A; Rosenberg SA; Hunt DF; Mariuzza RA; Topalian SL
J Immunol; 2013 Nov; 191(10):5097-106. PubMed ID: 24108701
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H
J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377
[TBL] [Abstract][Full Text] [Related]
3. A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen.
Bianchi V; Bulek A; Fuller A; Lloyd A; Attaf M; Rizkallah PJ; Dolton G; Sewell AK; Cole DK
J Biol Chem; 2016 Apr; 291(17):8951-9. PubMed ID: 26917722
[TBL] [Abstract][Full Text] [Related]
4. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
5. Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation.
Boots AM; Hubers H; Kouwijzer M; den Hoed-van Zandbrink L; Westrek-Esselink BM; van Doorn C; Stenger R; Bos ES; van Lierop MJ; Verheijden GF; Timmers CM; van Staveren CJ
Arthritis Res Ther; 2007; 9(4):R71. PubMed ID: 17645792
[TBL] [Abstract][Full Text] [Related]
6. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
Parkhurst MR; Riley JP; Robbins PF; Rosenberg SA
J Immunother; 2004; 27(2):79-91. PubMed ID: 14770079
[TBL] [Abstract][Full Text] [Related]
7. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
[TBL] [Abstract][Full Text] [Related]
8. T cell selection and differential activation on structurally related HLA-DR4 ligands.
Gebe JA; Novak EJ; Kwok WW; Farr AG; Nepom GT; Buckner JH
J Immunol; 2001 Sep; 167(6):3250-6. PubMed ID: 11544312
[TBL] [Abstract][Full Text] [Related]
9. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.
Vence LM; Wang C; Pappu H; Anson RE; Patel TA; Miller P; Bassett R; Lizee G; Overwijk WW; Komanduri K; Benjamin C; Alvarado G; Patel SP; Kim K; Papadopoulos NE; Bedikian AY; Homsi J; Hwu WJ; Boyd R; Radvanyi L; Hwu P
J Immunother; 2013 May; 36(4):276-86. PubMed ID: 23603862
[TBL] [Abstract][Full Text] [Related]
10. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.
Borbulevych OY; Baxter TK; Yu Z; Restifo NP; Baker BM
J Immunol; 2005 Apr; 174(8):4812-20. PubMed ID: 15814707
[TBL] [Abstract][Full Text] [Related]
11. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
12. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
[TBL] [Abstract][Full Text] [Related]
13. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
Denkberg G; Klechevsky E; Reiter Y
J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
[TBL] [Abstract][Full Text] [Related]
14. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
Nagorsen D; Panelli M; Dudley ME; Finkelstein SE; Rosenberg SA; Marincola FM
Gene Ther; 2003 Sep; 10(20):1754-65. PubMed ID: 12939642
[TBL] [Abstract][Full Text] [Related]
15. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope.
Bakker AB; van der Burg SH; Huijbens RJ; Drijfhout JW; Melief CJ; Adema GJ; Figdor CG
Int J Cancer; 1997 Jan; 70(3):302-9. PubMed ID: 9033632
[TBL] [Abstract][Full Text] [Related]
16. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells.
Kierstead LS; Ranieri E; Olson W; Brusic V; Sidney J; Sette A; Kasamon YL; Slingluff CL; Kirkwood JM; Storkus WJ
Br J Cancer; 2001 Nov; 85(11):1738-45. PubMed ID: 11742496
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
[TBL] [Abstract][Full Text] [Related]
18. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
19. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
20. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.
Kobayashi H; Lu J; Celis E
Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
